Evidence map›Paper›PMID 30190821›Full record

ReviewMelanoma management2014

How anti-PD1 treatments are changing the management of melanoma.

Peter Hersey, Hojabr Kakavand, James Wilmott, Andre van der Westhuizen, Stuart Gallagher, Kavitha Gowrishankar, Richard Scolyer

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Melanoma management, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.1field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Peter HerseyKolling Institute, Royal North Shore Hospital, St Leonards, NSW 2065, Australia.
Hojabr KakavandMelanoma Institute of Australia, Rocklands Road, North Sydney, NSW, Australia.
James WilmottMelanoma Institute of Australia, Rocklands Road, North Sydney, NSW, Australia.
Andre van der WesthuizenCalvary Mater Hospital, Sydney, NSW, Australia.
Stuart GallagherKolling Institute, Royal North Shore Hospital, St Leonards, NSW 2065, Australia.
Kavitha GowrishankarKolling Institute, Royal North Shore Hospital, St Leonards, NSW 2065, Australia.
Richard ScolyerMelanoma Institute of Australia, Rocklands Road, North Sydney, NSW, Australia.
Melanoma Institute Australia · AURoyal North Shore Hospital · AURoyal Prince Alfred Hospital · AUCalvary Hospital · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The introduction of immunotherapy based on the blockade of the PD1/PD-L1 checkpoints has been associated with high response rates and durable remissions of disease in patients with metastatic melanoma, to the extent that it is now considered the standard of care for a wide range of patients, irrespective of their

Indexed as

CD8 T cellsimmunotherapymelanomamonoclonal antibodiesPD1/PD-L1resistance factorssurvival outcomesTILs

Identifiers

PMID30190821
PMCPMC6094707
OpenAlexW2149715074

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.